The United Kingdom will offer an alternative vaccine to AstraZeneca for those under 30 years of age

Almost two-thirds of the 79 cases of thrombi detected so far in the United Kingdom correspond to women

The Regulatory Agency for Medicines and Health Products United Kingdom (MHRA, for its acronym in English) has concluded that the possible appearance of thrombi in people immunized against COVID-19 with vaccine AstraZeneca, should be offered an alternative drug to those who are less than 30 years old.

The regulator has estimated 79 cases of thrombi registered until the end of March in vaccinated people, 19 of which ended in death, reports the BBC network. Although researchers have not been able to determine what is caused by the injection, they do suspect that it may be a side effect.

However, the MHRA has clarified in any case that these are rare cases and that the benefits of the vaccine continue to outweigh the risks, in a line similar to that supported by the European Medicines Agency (EMA), which has updated this Wednesday his evaluation of the vaccine.

The risk assessment would vary in the case of the younger population, a priori less prone to serious harm from COVID-19. The group that advises the Government of Boris Johnson on vaccines (JCVI) is therefore committed to providing an alternative vaccine to the age group between 18 and 29 years.

Also, those with blood problems that make them more prone to thrombi should also check with their doctor before receiving the vaccine. Almost two-thirds of the cases detected so far in the United Kingdom correspond to women.